Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The company has been actively pursuing acquisitions to strengthen its core areas and diversify.
AmerisourceBergen has an impressive track of comfortably beating estimates in each of the four trailing quarters. It has an average positive surprise of 5.64%.
Currently, AmerisourceBergen has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.24, and the company reported EPS of $1.36.
Revenue: AmerisourceBergen posted revenues of $38.2 billion in the reported quarter, below the consensus estimate of $39.1 billion.
Key Stats: AmerisourceBergen expects earnings per share for full fiscal year 2017 in the range of $5.72–$5.92.
Share Performance: Shares have risen 19.87% over the past 3 months, while the Zacks categorized Medical - Dental Supplies sub industry has gained 6.77%.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Image: Bigstock
AmerisourceBergen (ABC) Q1 Earnings Beat, Sales Miss
Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The company has been actively pursuing acquisitions to strengthen its core areas and diversify.
AmerisourceBergen has an impressive track of comfortably beating estimates in each of the four trailing quarters. It has an average positive surprise of 5.64%.
Currently, AmerisourceBergen has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.24, and the company reported EPS of $1.36.
AmerisourceBergen Corporation (Holding Co) Price and EPS Surprise
AmerisourceBergen Corporation (Holding Co) Price and EPS Surprise | AmerisourceBergen Corporation (Holding Co) Quote
Revenue: AmerisourceBergen posted revenues of $38.2 billion in the reported quarter, below the consensus estimate of $39.1 billion.
Key Stats: AmerisourceBergen expects earnings per share for full fiscal year 2017 in the range of $5.72–$5.92.
Share Performance: Shares have risen 19.87% over the past 3 months, while the Zacks categorized Medical - Dental Supplies sub industry has gained 6.77%.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>